Clinical Trial Update: IFx-Hu2.0 Expanded Access Program

View source ↗

Summary

TuHURA Biosciences reports that the IFx-Hu2.0 Expanded Access Program is available for patients with cutaneous melanoma (Stage III/IV), Merkel cell carcinoma, a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma
• Cutaneous Squamous Cell Carcinoma
• Merkel Cell Carcinoma

Drugs mentioned

• IFx-Hu2.0

Snippet

Sponsor: TuHURA Biosciences, Inc. | Conditions: Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV | Status: AVAILABLE